Lexaria Bioscience (LEXX) Earnings Date, Estimates & Call Transcripts $0.88 +0.06 (+7.43%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Lexaria Bioscience Earnings Summary Lexaria Bioscience posted Q2 2025 earnings on April 14, 2025, reporting an EPS of -$0.15, which beat the consensus estimate of -$0.16 by $0.01. Quarterly revenue was reported to be $0.17 million, above analysts' expectations of $0.14 million. With a trailing EPS of -$0.59, Lexaria Bioscience's earnings are expected to grow next year, from ($0.59) to ($0.46) per share. Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportLatest Q2 2025 Earnings DateApr. 14EstimatedConsensus EPS (Apr. 14) -$0.16 Actual EPS (Apr. 14) -$0.15 Beat By $0.01 Actual Revenue (Apr. 14) $0.17M Get Lexaria Bioscience Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataLEXX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LEXX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Lexaria Bioscience Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.12-$0.12-$0.12Q2 20252-$0.14-$0.11-$0.13Q3 20252-$0.14-$0.11-$0.13Q4 20252-$0.15-$0.13-$0.14 FY 2025 7 -$0.55 -$0.47 -$0.51 Q1 20261-$0.14-$0.14-$0.14Q2 20261-$0.13-$0.13-$0.13Q3 20261-$0.12-$0.12-$0.12Q4 20261-$0.11-$0.11-$0.11 Lexaria Bioscience Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails4/14/2025Q2 2025-$0.16-$0.15+$0.01-$0.15$0.14M$0.17M1/10/2025Q1 2025-$0.12-$0.16 -$0.04-$0.16--11/26/2024Q4 2024-$0.11-$0.15 -$0.04-$0.15--7/12/2024Q3 2024-$0.09-$0.13 -$0.04-$0.13$0.15M$0.08M4/9/2024Q2 2024--$0.06--$0.06-$0.15M1/12/2024Q1 2024--$0.13--$0.13-$0.15M11/21/2023Q4 2023-$0.17-$0.12+$0.05-$0.12-- Lexaria Bioscience Earnings - Frequently Asked Questions When did Lexaria Bioscience announce their last quarterly earnings? Lexaria Bioscience (NASDAQ:LEXX) last announced its quarterly earning data on Monday, April 14, 2025. Learn more on LEXX's earnings history. Did Lexaria Bioscience beat their earnings estimates last quarter? In the previous quarter, Lexaria Bioscience (NASDAQ:LEXX) reported ($0.15) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.16) by $0.01. Learn more on analysts' earnings estimate vs. LEXX's actual earnings. How much revenue does Lexaria Bioscience generate each year? Lexaria Bioscience (NASDAQ:LEXX) has a recorded annual revenue of $460,000.00. How much profit does Lexaria Bioscience generate each year? Lexaria Bioscience (NASDAQ:LEXX) has a recorded net income of -$5.80 million. LEXX has generated -$0.59 earnings per share over the last four quarters. What is Lexaria Bioscience's EPS forecast for next year? Lexaria Bioscience's earnings are expected to grow from ($0.59) per share to ($0.46) per share in the next year. More Earnings Resources from MarketBeat Related Companies Cue Biopharma Earnings Results Werewolf Therapeutics Earnings Results Adverum Biotechnologies Earnings Results PDS Biotechnology Earnings Results Annovis Bio Earnings Results Gain Therapeutics Earnings Results NRx Pharmaceuticals Earnings Results Atara Biotherapeutics Earnings Results Kronos Bio Earnings Results Celularity Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong This page (NASDAQ:LEXX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEXX Stock Alerts